Cargando…

Assessing COVID-19 Booster Hesitancy and Its Correlates: An Early Evidence from India

The emergence of SARS-CoV-2 mutants, waning immunity, and breakthrough infections prompted the use of booster doses of the COVID-19 vaccine to fight against the pandemic. India started booster doses in January 2022 and it is critical to determine the intention of booster dose uptake and its correlat...

Descripción completa

Detalles Bibliográficos
Autores principales: Achrekar, Geetanjali C., Batra, Kavita, Urankar, Yashashri, Batra, Ravi, Iqbal, Naved, Choudhury, Sabiha A., Hooda, Deepti, Khan, Roohi, Arora, Suraj, Singh, Aditi, Chirico, Francesco, Sharma, Manoj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323084/
https://www.ncbi.nlm.nih.gov/pubmed/35891212
http://dx.doi.org/10.3390/vaccines10071048
_version_ 1784756463349006336
author Achrekar, Geetanjali C.
Batra, Kavita
Urankar, Yashashri
Batra, Ravi
Iqbal, Naved
Choudhury, Sabiha A.
Hooda, Deepti
Khan, Roohi
Arora, Suraj
Singh, Aditi
Chirico, Francesco
Sharma, Manoj
author_facet Achrekar, Geetanjali C.
Batra, Kavita
Urankar, Yashashri
Batra, Ravi
Iqbal, Naved
Choudhury, Sabiha A.
Hooda, Deepti
Khan, Roohi
Arora, Suraj
Singh, Aditi
Chirico, Francesco
Sharma, Manoj
author_sort Achrekar, Geetanjali C.
collection PubMed
description The emergence of SARS-CoV-2 mutants, waning immunity, and breakthrough infections prompted the use of booster doses of the COVID-19 vaccine to fight against the pandemic. India started booster doses in January 2022 and it is critical to determine the intention of booster dose uptake and its correlates. Therefore, the current cross-sectional study aimed to investigate booster dose acceptability and associated predictors among the Indian population. A convenience sampling technique was utilized to recruit a sample of 687 Indian residents. A 55-item psychometric validated survey tool was used to assess booster dose acceptability, vaccine literacy and vaccine confidence. Univariate, bivariate, and multivariate statistical methods were used to analyze the data. Over 50% of participants reported their willingness to take the booster dose. Among the group not willing to take the booster dose (n = 303, 44.1%), a significantly larger proportion of respondents were unvaccinated with the primary series (12.2% vs. 5.2%, p < 0.001), had an annual income below 2.96 lacs/annum (52.8% vs. 33.1, p < 0.001), were residents of rural areas (38.0% vs. 23.2%, p < 0.001), were not living with vulnerable individuals (78.5% vs. 65.2%, p < 0.001) and did not have family/friends who had tested positive for COVID-19 (54.6% vs. 35.1%, p = 0.001). Demographic, vaccine variables and multi-theory model subscales to predict the initiation of booster dose among hesitant participants were statistically significant, R(2) = 0.561, F (26, 244) = 11.978, p < 0.001; adjusted R(2) = 0.514. Findings of this study highlight the need to develop evidence-based interventions to promote vaccine uptake, particularly among hard-to-reach communities living in developing countries.
format Online
Article
Text
id pubmed-9323084
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93230842022-07-27 Assessing COVID-19 Booster Hesitancy and Its Correlates: An Early Evidence from India Achrekar, Geetanjali C. Batra, Kavita Urankar, Yashashri Batra, Ravi Iqbal, Naved Choudhury, Sabiha A. Hooda, Deepti Khan, Roohi Arora, Suraj Singh, Aditi Chirico, Francesco Sharma, Manoj Vaccines (Basel) Article The emergence of SARS-CoV-2 mutants, waning immunity, and breakthrough infections prompted the use of booster doses of the COVID-19 vaccine to fight against the pandemic. India started booster doses in January 2022 and it is critical to determine the intention of booster dose uptake and its correlates. Therefore, the current cross-sectional study aimed to investigate booster dose acceptability and associated predictors among the Indian population. A convenience sampling technique was utilized to recruit a sample of 687 Indian residents. A 55-item psychometric validated survey tool was used to assess booster dose acceptability, vaccine literacy and vaccine confidence. Univariate, bivariate, and multivariate statistical methods were used to analyze the data. Over 50% of participants reported their willingness to take the booster dose. Among the group not willing to take the booster dose (n = 303, 44.1%), a significantly larger proportion of respondents were unvaccinated with the primary series (12.2% vs. 5.2%, p < 0.001), had an annual income below 2.96 lacs/annum (52.8% vs. 33.1, p < 0.001), were residents of rural areas (38.0% vs. 23.2%, p < 0.001), were not living with vulnerable individuals (78.5% vs. 65.2%, p < 0.001) and did not have family/friends who had tested positive for COVID-19 (54.6% vs. 35.1%, p = 0.001). Demographic, vaccine variables and multi-theory model subscales to predict the initiation of booster dose among hesitant participants were statistically significant, R(2) = 0.561, F (26, 244) = 11.978, p < 0.001; adjusted R(2) = 0.514. Findings of this study highlight the need to develop evidence-based interventions to promote vaccine uptake, particularly among hard-to-reach communities living in developing countries. MDPI 2022-06-30 /pmc/articles/PMC9323084/ /pubmed/35891212 http://dx.doi.org/10.3390/vaccines10071048 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Achrekar, Geetanjali C.
Batra, Kavita
Urankar, Yashashri
Batra, Ravi
Iqbal, Naved
Choudhury, Sabiha A.
Hooda, Deepti
Khan, Roohi
Arora, Suraj
Singh, Aditi
Chirico, Francesco
Sharma, Manoj
Assessing COVID-19 Booster Hesitancy and Its Correlates: An Early Evidence from India
title Assessing COVID-19 Booster Hesitancy and Its Correlates: An Early Evidence from India
title_full Assessing COVID-19 Booster Hesitancy and Its Correlates: An Early Evidence from India
title_fullStr Assessing COVID-19 Booster Hesitancy and Its Correlates: An Early Evidence from India
title_full_unstemmed Assessing COVID-19 Booster Hesitancy and Its Correlates: An Early Evidence from India
title_short Assessing COVID-19 Booster Hesitancy and Its Correlates: An Early Evidence from India
title_sort assessing covid-19 booster hesitancy and its correlates: an early evidence from india
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323084/
https://www.ncbi.nlm.nih.gov/pubmed/35891212
http://dx.doi.org/10.3390/vaccines10071048
work_keys_str_mv AT achrekargeetanjalic assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia
AT batrakavita assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia
AT urankaryashashri assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia
AT batraravi assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia
AT iqbalnaved assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia
AT choudhurysabihaa assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia
AT hoodadeepti assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia
AT khanroohi assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia
AT arorasuraj assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia
AT singhaditi assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia
AT chiricofrancesco assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia
AT sharmamanoj assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia